Scripta Insights, the doctor-driven, AI-powered pharmacy navigation company that guides self-insured employers, health plans and their members to prescription savings, announces today its GLP-1 ...

Novo Nordisk is parting ways with its CEO Lars Fruergaard Jørgensen after the two parties mutually agreed that a change of ...

Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly.

Providers of compounded obesity drugs are finding—for now—a new way into the booming market by tweaking formulations.

FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight loss drug Wegovy, said ...

For every man who has cut carbs from his diet and dropped 10 pounds, there’s a woman who’s done exactly the same thing ...

In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.